Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors

Journal of Clinical Oncology

Volumn 23, Issue 29, 2005, Pages 7257-7264

  Sieben, Nathalie L G ^a   Oosting, Jan ^a   Flanagan, Adrienne M ^a   Prat, Jaime ^a   Roemen, Guido M J M ^a   Kolkman Uljee, Sandra M ^a   Van Eijk, Ronald ^a   Cornelisse, Cees J ^a   Fleuren, Gert Jan ^a   Van Engeland, Manon ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RNA; B RAF KINASE; BRAF PROTEIN, HUMAN; DUSP4 PROTEIN, HUMAN; GELATINASE B; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROTEIN TYROSINE PHOSPHATASE;

ARTICLE; BENIGN TUMOR; CANCER GENETICS; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; DUSP 4 GENE; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; OVARY TUMOR; PATHOGENESIS; PRIORITY JOURNAL; SERPINA 5 GENE; TUMOR SUPPRESSOR GENE; DNA MICROARRAY; GENETICS; MUTATION; NEOPLASM; ONCOGENE RAS;

FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENES, RAS; GENES, TUMOR SUPPRESSOR; HUMANS; MATRIX METALLOPROTEINASE 9; MUTATION; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROTEIN C INHIBITOR; PROTEIN-TYROSINE-PHOSPHATASE; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 33644687627     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.2541     Document Type: Article

References (27)

1. Scully RE, Young RH, Clement PB: Surface epithelial-stromal tumors: Serous tumors, in Rosai J and Sobin LH (eds): Atlas of Tumor Pathology: Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament. Washington, DC, Armed Forces Institute of Pathology, 1998, pp 51-79
2. Hart WR: Borderline epithelial tumors of the ovary. Mod Pathol 18:S33-S50, 2005 (suppl 21
3. Prat J, De Nictolis M: Serous borderline tumors of the ovary: A long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol 26:1111-1128, 2002
4. Prat J: Surface epithelial-stromal tumors: Serous tumors, in Prat J (ed): Pathology of the Ovary. Philadelphia, PA, J. Saunders, 2004, pp 83-111
5. Singer G, Oldt R, III, Cohen Y, et al: Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95:484-486, 2003
6. Sieben NL, Macropoulos P, Roemen GMJM, et al: In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 202:336-340, 2004
7. Aguirre Ghiso JA, Alonso DF, Farias EF, et al: Deregulation of the signaling pathways controlling urokinase production: Its relationship with the invasive phenotype. Eur J Biochem 263:295-304, 1999
8. Affymetrix GeneChip Expression Analysis Technical Manual. Santa Clara, CA, Affymetrix Inc. 2001
9. Cope LM, Irizarry RA, Jaffee H, et al: A benchmark for Affymetrix GeneChip expression measures. Bioinformatics 20:323-331, 2004
10. Bolstad BM, Irizarry RA, Astrand M, et al: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185-193, 2003
11. Goeman JJ, van de Gear SA, de Kort F, et al: A Global Test for groups of genes: Testing association with a clinical outcome. Bioinformatics 20:93-99, 2004
12. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98:5116-5121, 2001
13. Cleutjens JP, Kandala JC, Guarda E, et al: Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 27:1281-1292, 1995
14. Gilks CB, Vanderhyden BC, Zhu S, et al: Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 96:684-694, 2005
15. Meinhold-Heerlein I, Bauerschlag D, Hilpert F, et al: Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24:1-13, 2004
16. Schmalfeldt B, Prechtel O, Harting K, et al: Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and urokinase type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 7:2396-2404, 2001
17. Misra-Press A, Rim CS, Yao H, et al: A novel mitogen-activated protein kinase phosphatase: Structure, expression and regulation. J Biol Chem 270:14587-14596, 1995
18. Yip-Schneider MT, Lin A, Marshall MS: Pancreatic tumor cells wth mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase Phosphatatse-2. Biochem Biophys Res Commun 280:992-997, 2001
19. Armes JE, Hammet F, de Silva M, et al: Candidate tumor suppressor genes on chromosome 8p in early-onset and high grade breast cancers. Oncogene 23:5697-5702, 2004
20. Wang Y, Klijn JGM, Sieuwerts AM, et al: Gene-expression profites to predict distant metastasis of lymph node negative primary breast cancer. Lancet 365:671-678, 2005
21. Jackson TP, Cooper ST, Church FC: Assessment of the interaction between urokinase and reactive site mutants of protein c inhibitor. J Protein Chem 16:819-828, 1997
22. Michael IP, Sotiropoulou G, Pampalakis G, et al: Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J Biol Chem 280:14628-14636, 2005
23. Kim H, Scorilas A, Katsaros D, et al: Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer 84:643-650, 2001
24. Cao Y, Becker C, Lundwall A, et al: Expression of protein C inhibitor (PCI) in benign and malignant prostate tissues. Prostate 57:196-204, 2003
25. Pohl G, Ho CL, Kurman RJ, et al: Inactivation of the mitogen-activated protein kinase pathway as a potential target based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 65:1984-2000, 2005
26. Lin AW, Barradas M, Stone JC, et al: Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK. mitogenic signaling. Genes Dev 12:3008-3019, 1998
27. Yang S, Farraye FA, Mack CBS, et al: BRAF and KRAS mutations in hyperplastic polyps and serrated adenomas of the colorectum: Relationship to histology and CpG island methylation status. Am J Surg Pathol 28:1452-1459, 2004